Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Safety and Efficacy Assessment of Stérimar Stop and Protect Cold for Adults and Stérimar Blocked Nose in Common Cold: A Randomized, Double-blind, Controlled Parallel-group, Clinical Study (CROSBI ID 303671)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Sbrocca, Federica ; Saaid, Amina ; Culig, Josip Safety and Efficacy Assessment of Stérimar Stop and Protect Cold for Adults and Stérimar Blocked Nose in Common Cold: A Randomized, Double-blind, Controlled Parallel-group, Clinical Study // Acta Scientific Otolaryngology, 4 (2022), 1; 7-17

Podaci o odgovornosti

Sbrocca, Federica ; Saaid, Amina ; Culig, Josip

engleski

Safety and Efficacy Assessment of Stérimar Stop and Protect Cold for Adults and Stérimar Blocked Nose in Common Cold: A Randomized, Double-blind, Controlled Parallel-group, Clinical Study

Background: Current treatment options for common cold focus on symptomatic relief. Nasal irrigation is a safe, inexpensive and effective adjunct treatment to reduce common cold-associated nasal congestion ; it also improves quality of life and decreases medication use. Purpose: The objective of this work was to investigate safety and efficacy of a novel microfiltered hypertonic seawater solution enriched with hyaluronic acids, eucalyptus oil and copper salts (SSPCA) on relieving common cold symptoms in comparison to a hypertonic seawater solution enriched with copper salts only (SBN). Methods: In total, 102 common cold patients were randomized to use SSPCA (n = 51) or SBN (n = 51) until their common cold episode was resolved (maximum 14 days). Illness severity evaluated by means of the validated 21-item Wisconsin Upper Respiratory Symptom Survey (WURSS-21) was the primary endpoint. Illness duration, use of rescue medication, patient satisfaction and acceptability were secondary endpoints measured through patient diaries. In addition, nasal presence of 24 airway pathogens was screened via RT-PCR before and after treatment. Results: Based on subjective patient diaries, SSPCA was as effective as SBN in reducing overall illness/symptom severity, improving quality of life and satisfying patient expectations. SSPCA had a faster onset of action than SBN in nasal decongestion (p = 0.0056), symptom and breathing relief (p = 0.0028 and p = 0.0128, respectively), stopping cold symptoms (p = 0.0002), and improving nasal well-being (p = 0.0279). Amount of airway pathogens - including rhino- and adenoviruses - was significantly lower after the treatment compared to pre-treatment, with no difference between groups. No adverse events were reported. Conclusion: Both SSPCA and SBN appear to be safe and effective solutions that enable symptomatic relief and decrease the presence of nasal viruses in common cold patients. However, SSPCA had a faster onset of action compared to SBN in nasal decongestion and breathing relief, improving common cold symptoms and nasal well-being.

Nasal Irrigation ; Common Cold ; Hypertonic Solutions ; Seawater ; Hyaluronic Acid ; Copper

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

4 (1)

2022.

7-17

objavljeno

2582-5550

Povezanost rada

Kliničke medicinske znanosti